Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21657442 | 0.87 | TDP1 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL23499716 | 0.87 | TDP1 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL19451348 | 0.86 | TDP1 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18886420 | 0.86 | TDP1 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25063467 | 0.85 | TDP1 (0.44) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21082300 | 0.85 | TDP1 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25756409 | 0.85 | TDP1 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL22256341 | 0.85 | TDP1 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL13699508 | 0.85 | TDP1 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL3198212 | 0.85 | TDP1 (0.49) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399208-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | Rigel Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023038815-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2022187303-A1 | A METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11370787-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114364674-A | Pyrazole compounds, formulations thereof, and methods of using the compounds and/or formulations | 里格尔药品股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210061798-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061798-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | IRAK1, IRAK3, IRAK2 | TDP1 618/4885CA12 4880/4885CA1 4790/4885 |
| US-11370787-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | IRAK1, IRAK3, IRAK2 | TDP1 618/4885CA12 4880/4885CA1 4790/4885 |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | IRAK1, IRAK3, IRAK2 | TDP1 618/4885CA12 4880/4885CA1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.